Product
R21/Matrix-M
4 clinical trials
1 indication
Indication
MalariaClinical trial
A Cluster-randomised, Open-label Trial to Compare the Impact of Combined Mass Vaccine and Drug Administrations, Mass Drug Administration, Mass Vaccinations, or no Intervention on Plasmodium Falciparum Malaria TransmissionStatus: Not yet recruiting, Estimated PCD: 2028-02-01
Clinical trial
A Randomized, Open Label, Single Centre, Phase 2 Trial of the Malaria Vaccine, R21/Matrix-M, to Assess Safety and Immunogenicity of the Vaccine in Thai AdultsStatus: Completed, Estimated PCD: 2023-06-08
Clinical trial
A Phase Ib Trial to Evaluate the Safety and Immunogenicity of R21/Matrix-M in a Single and Two Vial Presentation, With Different Immunisation Schedules, and When Co-Administered With EPI Vaccines in African ChildrenStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A Phase III Randomized Controlled Multi-centre Trial to Evaluate the Efficacy of the R21/Matrix-M Vaccine in African Children Against Clinical MalariaStatus: Active (not recruiting), Estimated PCD: 2023-03-21